Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Centre hospitalier de l'Université de Montréal (CHUM)
Seagen Inc.
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The First Affiliated Hospital with Nanjing Medical University
Eli Lilly and Company
Pfizer
Genmab
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
Pusan National University Hospital
Jonsson Comprehensive Cancer Center
University of California, Davis
Arcus Biosciences, Inc.
University Hospital Heidelberg
University Hospital Heidelberg
M.D. Anderson Cancer Center
AstraZeneca
M.D. Anderson Cancer Center
City of Hope Medical Center
AstraZeneca
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Amgen
M.D. Anderson Cancer Center
Istituto Oncologico Veneto IRCCS
University of California, Davis
H. Lee Moffitt Cancer Center and Research Institute
Replimune Inc.
Johannes Gutenberg University Mainz
City of Hope Medical Center
Carevive Systems, Inc.
University of Pennsylvania
City of Hope Medical Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Pfizer
Providence Health & Services